Samuel Álvarez-Arguedas is doing his PhD in Biochemistry and Molecular Biology at the University of Zaragoza, Spain, under the supervision of Prof. Carlos Martín, focusing on the study and characterization of the new tuberculosis vaccine, MTBVAC. Focused in the effect of MTBVAC on immunotherapy of bladder cancer cells and the study of the transcriptoma in vivo of Mycobacterium tuberculosis, he is doing an internship in the group of Roland Brosch to study the rol of the PE/PPE proteins in MTBVAC. He is interested in knowing the contribution to the immunogenicity and localization of the PE/PPE proteins of ESX-1 and ESX-5 locus.
Click to view graph
Connections
Former Teams
-
Évaluation d’une molécule dénommée “anticorps anti-CD31” pour le traitement des maladies cardio-vasculaires (CD31)Hélène Laude
-
Étude des interactions entre virus et insectes dans les arboviroses : LIPOARBO-IVI (2023-006)Louis Lambrechts
-
HelPathSophie Bachellier-Bassi
-
Proposed approach to evaluate the potential of avian influenza viruses of concern to undergo genetic reassortment and acquire an MxA-resistant NP segmentMarie-Anne Rameix-Welti
-
PvSeroRDT: A point-of-care serological rapid diagnostic test for risk of Plasmodium vivax hypnozoite infectionMichael White
-
Initiative de renforcement des capacités éthiques en Côte d’Ivoire (CECaBI II)Fanny Momboisse